The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months

Diabetes Care

Volumn 38, Issue 5, 2015, Pages 940-942

  Sosenko, Jay M ^a   Skyler, Jay S ^a   Beam, Craig A ^b   Boulware, David ^c   Mahon, Jeffrey L ^d   Krischer, Jeffrey P ^c   Greenbaum, Carla J ^e   Rafkin, Lisa E ^a   Matheson, Della ^a   Herold, Kevan C ^f   Palmer, Jerry P ^g  

^a UNIVERSITY OF MIAMI   (United States)

^b WESTERN MICHIGAN UNIVERSITY HOMER STRYKER MD SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e BENAROYA RESEARCH INSTITUTE   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUCOSE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; DIET RESTRICTION; DISEASE COURSE; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MATHEMATICAL PARAMETERS; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PS6M SCALE; RISK ASSESSMENT; SCORING SYSTEM; ADOLESCENT; DIABETES MELLITUS, TYPE 1; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; METABOLISM; PATIENT ACUITY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; AUTOANTIBODIES; BIOMARKERS; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; MALE; PATIENT ACUITY; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84958651977     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2787     Document Type: Article

References (10)

1. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691
2. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-1076
3. Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-931
4. Sosenko JM, Palmer JP, Greenbaum CJ, et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643-649
5. Sosenko JM, Palmer JP, Rafkin LE, et al, .; Diabetes Prevention Trial-Type 1 Study Group. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 participants. Diabetes Care 2010;33:620-625
6. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
7. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al, .; TrialNet Natural History Committee, ; Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009;10:97-104
8. Little RR, Rohlfing CL, Tennill AL, et al. Standardization of C-peptide measurements. Clin Chem 2008;54:1023-1026
9. Sosenko JM, Skyler JS, Mahon J, et al, .; TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Validation of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787
10. Krischer JP; Type 1 Diabetes TrialNet Study Group. The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia 2013;56:1919-1924